Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.61 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10915440 | 0.88 | IMPDH2 (0.54) | IMPDH2IMPDH1MAPTGAATSHR | |
| SCHEMBL30839714 | 0.83 | MAPT (0.59) | IMPDH2IMPDH1MAPTGAATSHR | |
| SCHEMBL347390 | 0.83 | MAPT (0.59) | IMPDH2IMPDH1MAPTGAATSHR | |
| Hydrochloric Acid SCHEMBL10604756 | 0.81 | MAPT (0.57) | IMPDH2IMPDH1MAPTGAATSHR | |
| SCHEMBL6753659 | 0.80 | MAPT (0.53) | IMPDH2IMPDH1MAPTGAATSHR | |
| SCHEMBL6747997 | 0.80 | IMPDH2 (0.42) | IMPDH2IMPDH1MAPTGAATSHR | |
| SCHEMBL10915716 | 0.79 | IMPDH2 (0.59) | IMPDH2IMPDH1MAPTGAATSHR | |
| SCHEMBL3411035 | 0.79 | IMPDH2 (0.58) | IMPDH2IMPDH1MAPTGAATSHR | |
| SCHEMBL311721 | 0.78 | MAPT (0.53) | IMPDH2IMPDH1MAPTGAATSHR | |
| SCHEMBL29764084 | 0.78 | MAPT (0.53) | IMPDH2IMPDH1MAPTGAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745456-B2 | Synthesis and antimicrobial activity of novel dicationic “reversed amidines” | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745456-B2 | Synthesis and antimicrobial activity of novel dicationic “reversed amidines” | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-06-29 | — | — | US | disclosed |
| US-7410989-B2 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2008-08-12 | — | — | US | disclosed |
| US-7410999-B2 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | UNIVERSITY OF NORTH CAROLINIA AT CHAPEL HILL (US) | 2008-08-12 | — | — | US | disclosed |
| US-20080058372-A1 | Synthesis and antimicrobial activity of novel dicationic ''reversed amidines'' | The University of North Carolina at Chapel Hill: | 2008-03-06 | — | — | US | disclosed |
| EP-1399163-B1 | COMPOUNDS, METHODS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF BOVINE VIRAL DIARRHEA VIRUS (BVDV) INFECTION AND HEPATITIS C VIRUS (HCV) INFECTION | UNIV NORTH CAROLINA (US) | 2007-10-10 | — | — | EP | disclosed |
| EP-1837024-A2 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2007-09-26 | — | — | EP | disclosed |
| US-7241795-B2 | Synthesis and antimicrobial activity of novel dicationic “reversed amidines” | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241795-B2 | Synthesis and antimicrobial activity of novel dicationic “reversed amidines” | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2007-07-10 | — | — | US | disclosed |
| US-20070072878-A1 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-03-29 | — | — | US | disclosed |
| US-6737440-B2 | 2,5-BIS ((ALKYL (OR ARYL) IMINO) AMINOPHENYL) FURANS, THIOPHENES OR PYRROLES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2004-05-18 | — | — | US | disclosed |
| EP-1399163-A2 | COMPOUNDS, METHODS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF BOVINE VIRAL DIARRHEA VIRUS (BVDV) INFECTION AND HEPATITIS C VIRUS (HCV) INFECTION | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2004-03-24 | — | — | EP | disclosed |
| US-6706754-B2 | ANTIPROTOZOA AGENTS, PARASITICIDES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2004-03-16 | — | — | US | disclosed |
| US-20030199521-A1 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-23 | — | — | US | disclosed |
| EP-1337510-A2 | SYNTHESIS AND ANTIMICROBIAL ACTIVITYOF NOVEL DICATIONIC \"REVERSED AMIDINES\ | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2003-08-27 | — | — | EP | disclosed |
| US-20030083362-A1 | Synthesis and antimicrobial activity of novel dicationic\"reversed amidines\ | GEORGIA STATE UNIVERSITY | 2003-05-01 | — | — | US | disclosed |
| US-20020156098-A1 | Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis | ARMY, UNITED STATES | 2002-10-24 | — | — | US | disclosed |
| WO-2002057224-A2 | SYNTHESIS AND ANTIMICROBIAL ACTIVITYOF NOVEL DICATIONIC 'REVERSED AMIDINES' | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002055025-A2 | COMPOUNDS, METHODS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF BOVINE VIRAL DIARRHEA VIRUS (BVDV) INFECTION AND HEPATITIS C VIRUS (HCV) INFECTION | UNIV NORTH CAROLINA (US) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002036588-A2 | REVERSED AMIDINES AND METHODS OF USING FOR TREATING, PREVENTING, OR INHIBITING LEISHMANIASIS | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND (US) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199521-A1 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | OAT, GYS2, HCCS | IMPDH2 1034/4885IMPDH1 738/4885MAPT 1442/4885 |
| US-20030083362-A1 | Synthesis and antimicrobial activity of novel dicationic\"reversed amidines\ | HRH4, TLR7, DDAH1 | IMPDH2 1053/4885IMPDH1 798/4885MAPT 4854/4885 |
| US-20070072878-A1 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | OAT, GYS2, HCCS | IMPDH2 1034/4885IMPDH1 738/4885MAPT 1442/4885 |
| US-20080058372-A1 | Synthesis and antimicrobial activity of novel dicationic ''reversed amidines'' | TLR7, DHRS9, TLR8 | IMPDH2 2630/4885IMPDH1 2176/4885MAPT 4844/4885 |
| US-20020156098-A1 | Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis | ARG1, NAT1, CTSA | IMPDH2 2217/4885IMPDH1 1643/4885MAPT 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.